In this free webinar, attendees will gain insights into the current and future trends, opportunities and considerations for the development of inhaled biologics. The featured speakers will discuss factors such as the biologic's dose/regimen, physical/chemical properties and patient and commercial requirements, which help determine the technologies that can be used to develop inhaled biologics. They will also speak about how inhaled biologics address important challenges in vaccine development and specific considerations for delivering vaccines via inhalation.
TORONTO, May 7, 2024 /PRNewswire-PRWeb/ -- Development of biologics continues to increase, with a substantial portion of pipeline molecules falling under this umbrella. Although injections remain a common delivery route, inhaled biologics are growing their share of the development pipeline. These therapies have the potential to expand treatment options across a wide range of therapeutic areas, from lung infectious diseases to acute and chronic lung and systemic diseases. Inhaled vaccines also present a valuable opportunity within this space.
To take full advantage of these benefits, a thorough understanding of the unique considerations for inhaled biologic development is important. From small and large peptides and proteins to RNA and gene-based therapies and more, the inhaled biologics space presents a wealth of opportunities for growth, but there are also key considerations that must be addressed. Developing biologics that can withstand formulation and delivery via inhalation is a complex process, requiring specific capabilities and expertise.
In this webinar, the expert speakers will focus on the benefits and considerations for inhaled vs. injectable biologics. They will discuss factors such as the biologic's dose/regimen, physical/chemical properties and patient and commercial requirements, which help determine the technologies that can be used to develop inhaled biologics. They will also speak about how inhaled biologics address important challenges in vaccine development and specific considerations for delivering vaccines via inhalation.
The participants can also expect a comprehensive overview of the inhaled biologics market as it stands today, with an eye toward future opportunities and challenges. The webinar will cover inhaled biologics from vaccines to drugs for chronic use, touching on the importance of being technology agnostic in the beginning and strategies for an optimized development process.
Register for this webinar today to gain insights into the current and future trends, opportunities and considerations for the development of inhaled biologics.
Join featured speakers John Patton, Head Kindeva SAB, ; Keith Ung, Director and Bay Area Site Head, Kindeva Drug Delivery; Andy Clark, President and General Manager, Aerogen Pharma Corporation; and Jeff Weers, Chief Technology Officer, Cystetic Medicines, Inc., for the on Wednesday, May 22, 2024, at 11am EDT (4pm BST/UK). This webinar is also co-promoted by .
For more information, or to register for this event, visit .
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit
For information about hosting a webinar visit
Media Contact
Ayesha Rashid, Xtalks, +1 (416) 977-6555 x272, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article